Transurethral ethanol ablation of the prostate (TEAP) has emerged among the treatment alternatives to transurethral resection of prostate as a promising minimally invasive therapy that can be performed on an outpatient basis with fewer complications. It was introduced approximately 5 years ago, and to date, 12-month results are encouraging. We herein review the procedure and outcomes of TEAP.
No takes yet. Share an insight, caveat, or question.
Buchholz et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: